Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association
This page was last updated: Jun 03, 2023
This page was last updated: Jun 03, 2023
This issue is sponsored by the Midwest Lipid Association
This page was last updated: Jun 13, 2023
This issue is sponsored by the Southwest and Pacific Lipid Associations
This page was last updated: Feb 21, 2023
Dyslipidemia, or high cholesterol, means you have too many lipids (fat) in your blood. Nutrition interventions in youth with dyslipidemia provide short- and long-term benefits without adverse effects on growth or maturation. Counseling by a registered dietitian nutritionist (RDN) is strongly recommended to help youth and their families successfully alter dietary intake to meet nutritional needs, provide ongoing support, and encourage long-term adherence to healthy nutrition and exercise patterns.
This page was last updated: Sep 10, 2022
Statin-associated muscle symptoms (SAMS) are the most common form of statin intolerance and are associated with increased risk of cardiovascular events that manifest from statin underutilization and discontinuation.
This page was last updated: Sep 10, 2022
MIAMI, Fla. – (May 17, 2019) -- The National Lipid Association (NLA) today announced the release of an official scientific statement on Lipoprotein(a) [Lp(a)] clinical use at the NLA 2019 Scientific Sessions, May 16 – 19 at the Turnberry Isle Miami in Aventura, Florida.
Created by an international team of clinical lipid experts (see list on page 2), the statement is designed as a comprehensive source of guidance for medical professionals making decisions to improve the health and well-being of children and adults at risk of premature cardiovascular disease.
The National Lipid Association now has 100 lifetime members, which means $100,000 has been set aside for fellowship training programs in lipidology. The NLA is offering this program only through the end of 2013.
How does lifetime membership work? It’s simple:
The National Lipid Association (NLA) today announced the publication of a new meta-analysis evaluating the impact of low-density lipoprotein cholesterol (LDL-C) lowering on major adverse cardiovascular events (MACE) in primary prevention populations. The study synthesizes data from randomized trials of both statin and non-statin therapies and updates a landmark 2012 analysis conducted by the Cholesterol Treatment Trialists’ Collaboration (CTTC).
The National Lipid Association has released an updated expert clinical consensus on the identification, diagnosis, and management of familial hypercholesterolemia (FH) available open access in the Journal of Clinical Lipidology. This updated expert consensus highlights advances in diagnosis, genetics, and treatment for this lifelong condition that requires lifelong attention.
Key updates in the new NLA guidance include:
The mission of the National Lipid Association (NLA) is “to enhance the science and practice of lipidology and promote optimal cardiometabolic health.” The NLA leadership acknowledges the publication of the 2025-2030 Dietary Guidelines for Americans (DGAs), which are used to inform dietary guidance and nutrition policies for the general population.